Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ME2 | P23368 | 2/20 | 0.36 |
| ▸ | ME1 | P48163 | 2/20 | 0.36 |
| ▸ | ME3 | Q16798 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593569 | 0.91 | RORC (0.37) | GRM5KMT2AME2ME1ME3 | |
| SCHEMBL3590902 | 0.88 | GPR119 (0.44) | KMT2AMAPT | |
| SCHEMBL105484 | 0.83 | HTR1A (0.42) | — | |
| SCHEMBL106074 | 0.77 | GAA (0.42) | KMT2AHTT | |
| SCHEMBL3592710 | 0.72 | GRM5 (0.41) | GRM5KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL103414 | 0.72 | GRM5 (0.41) | GRM5KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3601001 | 0.72 | IDO1 (0.37) | KMT2AALDH1A1SMN1; SMN2MAPTRORC | |
| SCHEMBL102390 | 0.69 | MC4R (0.36) | SMN1; SMN2POLBMAPT | |
| SCHEMBL132842 | 0.64 | GRM5 (0.42) | GRM5ALDH1A1RORCLMNA | |
| SCHEMBL106403 | 0.63 | RORC (0.39) | GRM5KMT2AALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | GRM5 1608/4885KMT2A 2327/4885ME2 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.